Physician

Emily S Riser, MD

According to 2025 Medicare claims, Emily Riser, MD (NPI: 1124115068) practices neurology in the Birmingham, AL market, with the plurality of this provider's patient population coming from Jefferson, AL. This provider's primary affiliated billing organization is ALABAMA NEUROLOGY ASSOCIATES (NPI: 1679642805; TIN: 63-0976742) and primary practice location at 35209-4111.

Riser's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 215 traditional Medicare patients, billed 34,968 HCPCS/CPT codes, and received $942,505 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 7,458 prescription claims across 574 beneficiaries totaling $6,902,911 in drug costs, led by Soliris (Eculizumab). DME data shows 92 claims. Open Payments data shows 323 records totaling $1,271,831. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $126,363 to $942,505. In contrast, Part D prescription costs have declined steadily, from $11,371,735 to $6,902,911. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $93,195 to $25,602.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	312	4,543	$126,363
2016	368	4,437	$127,966
2017	269	6,301	$178,041
2018	256	7,073	$199,572
2019	317	15,066	$357,222
2020	279	39,713	$1,085,802
2021	214	31,356	$1,041,156
2022	195	29,787	$921,755
2023	168	23,915	$871,773
2024	215	34,968	$942,505

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	383	6,440	$11,371,735
2016	486	7,097	$12,953,848
2017	499	7,559	$12,358,409
2018	445	6,838	$11,715,898
2019	425	6,305	$9,946,665
2020	405	6,451	$9,945,124
2021	415	6,049	$9,849,613
2022	476	6,382	$7,675,168
2023	487	6,172	$7,161,604
2024	574	7,458	$6,902,911

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	22	$5,440
2016	N/R	60	$1,785
2017	N/R	36	$30,906
2018	N/R	56	$2,543
2019	N/R	17	$613
2020	N/R	86	$118,403
2021	N/R	152	$203,451
2022	N/R	126	$144,973
2023	N/R	121	$112,221
2024	N/R	92	$124,416

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	16	26	$81
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	185	266	$73
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	25	156	$40
96375	Injection of additional new drug or substance into vein	21	67	$10
J2919	Injection, methylprednisolone sodium succinate, 5 mg	26	8,049	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Soliris	Eculizumab	30	826	$1,595,642
Kesimpta Pen	Ofatumumab	74	2,176	$682,697
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	114	3,073	$483,139
Aubagio	Teriflunomide	39	1,170	$348,551
Gamunex-C	Immune Globul G/Gly/Iga Avg 46	29	812	$314,446

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	21	$80,422
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	N	N/R	18	$36,892
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	18	$5,934
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	14	$997
K0552	Supplies for external non-insulin drug infusion pump, syringe type cartridge, sterile, each	N	N/R	21	$172

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	194	$33,045	Alexion Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	129	$1,238,786	Genentech, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Emily S. Riser, MD?

Tedicare shows public-source Medicare data for Emily S. Riser, MD (NPI 1124115068), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Emily S. Riser, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Emily S. Riser, MD?

Emily S. Riser, MD is linked to ALABAMA NEUROLOGY ASSOCIATES (billing NPI 1679642805) in the available physician profile data.

Does Emily S. Riser, MD have Open Payments data?

Emily S. Riser, MD has 323 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.